Korsana Biosciences, Inc.
KRSA
NASDAQ·Healthcare·Biotechnology·Mkt cap $142.7M
$31.20
▼ -2.50%
P/E
-2.59
Mkt Cap
$142.7M
52-Wk Range
$7.19–$59.36
52-Week Range
$7.19 - $59.36
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 82.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Revenue decline expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+25.9% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KRSA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$2.87.
Reported EPS · last 4Q
Q2 26
-$2.87
Q1 26
-$5.32
Q4 25
-$1.75
Q3 25
-$2.10
Revenue trend · last 8Q
—
—
—
—
+351%
-43%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$194.0K
$1.8M
$81.0K
$93.0K
$875.0K
$1.0M
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Sep 28, 2026
vs Industry
How KRSA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.